

1 **Interferon Gamma Release Assays for Latent *Mycobacterium tuberculosis* Detection in Elderly**
2 **Hispanics**

3
4 **Running title:** LTBI testing with IGRAs in elderly Hispanics

5
6 Julia M. Scordo, PhD ^{a,b}, Génesis P. Aguillón-Durán, MSc ^c, Doris Ayala, BSc ^d, Ana Paulina Quirino-Cerrillo,
7 BSc ^d, Eminé Rodríguez-Reyna, BSc ^{c,*}, Mateo Joya-Ayala ^d, Francisco Mora-Guzmán, MD^{c,*}, Eder
8 Ledezma-Campos, MD ^c, Alejandro Villafañez, MD ^e, Larry S. Schlesinger, MD ^a, Jordi B. Torrelles, PhD ^a,
9 Joanne Turner, PhD ^a, Blanca I. Restrepo, PhD ^{d,f,**}

10
11 ^a Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San
12 Antonio, TX, USA; ^b The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA;
13 ^c Secretaria de Salud de Tamaulipas, Reynosa 88630, Matamoros 87370 and Ciudad Victoria 87000,
14 Tamaulipas, México; ^d University of Texas Health Science Center at Houston, School of Public Health,
15 Brownsville campus, Brownsville, TX 78520, USA; ^e Casa Club del Adulto Mayor, Sistema para el
16 Desarrollo Integral de la Familia, Matamoros, Tamaulipas, Mexico; ^f School of Medicine, South Texas
17 Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Edinburg, TX 78541, USA

18 * Deceased

19 ** **Corresponding author:** Dr. Blanca I. Restrepo, Blanca.i.restrepo@uth.tmc.edu; 1214 W Schunior,
20 UTRGV-Edinburg campus, Edinburg, TX

21
22 **Funding:** Research reported in this publication was supported by the National Institute On Aging of the
23 National Institutes of Health under Award Number P01AG051428[P01-AG051428 to JT, LSS, BIR and JBT]
24 and NIH/NIA NRSA T32-AG021890 to JMS. The content is solely the responsibility of the authors and
25 does not necessarily represent the official views of the National Institutes of Health

26
27 **Conflict of Interests:** BIR received funding support from Oxford Immunotec for an unrelated study.
28 Other authors declare no conflicts of interest.

29
30 **Word Counts:** Text 3302; Abstract 252

31
32 **Number of tables:** 2; **Number of figures:** 3

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64

Keywords: diagnosis, elderly, IGRA, Latent TB infection, *Mycobacterium tuberculosis*

Abbreviations: Interferon Gamma Release Assays (IGRAs); latent *Mycobacterium tuberculosis* infection (LTBI); tuberculosis (TB); recent TB contacts (ReC); community controls (CoC); QuantiFERON (QFT); tuberculin skin test (TST)

65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90

SUMMARY

Background. Aging is a tuberculosis co-morbidity. Interferon Gamma Release Assays (IGRAs) are used to detect latent *Mycobacterium tuberculosis* (*M.tb*) infection (LTBI) in adults, but their performance in the elderly is not well-established. We aim to evaluate the performance of IGRAs for LTBI detection in healthy elderly Hispanics with recent, remote or no history of *M.tb* exposure.

Study Design and Methods. Cross-sectional study in Hispanic elderly (60+y) and adult (18-50y) recent TB contacts (ReC) or community controls (CoC). LTBI was based on a positive T-SPOT.TB and/or QuantiFERON-Gold in-tube or –Plus assay.

Results. We enrolled 193 CoC (119 adults/74 elderly) and 459 ReC (361 adults/98 elderly). LTBI positivity increased with age in CoC (range 19-59%; trend $p < 0.001$), but was similar in ReC (range 59-69%; trend $p = 0.329$). The elderly had lower concordance between IGRAs (kappa 0.465 vs. 0.688 in adults) and more inconclusive results (indeterminate/borderline; 11.6% vs. 5.8% in adults; $p = 0.012$). Exclusion of inconclusive results improved concordance between assays, notably in elderly ReC, who have the highest TB risk (from kappa 0.532 to 0.800). When both IGRAs were done simultaneously, inconclusive results were resolved in all cases as positive or negative with the other IGRA. The magnitude of the response to *M.tb* peptides used in the assays was similar between age groups, but responsiveness to mitogens was lower in the elderly.

Conclusions. IGRAs are suitable for LTBI detection in the elderly. Discordant and inconclusive findings are more prevalent in the elderly, but results were resolved when performing different IGRAs simultaneously in the same participant.

91 INTRODUCTION

92 *Mycobacterium tuberculosis* (*M.tb*) infected nearly 10 million people and caused 1.8 million tuberculosis
93 (TB) deaths worldwide in 2020.¹ An estimated one quarter of the world's population has a latent
94 *Mycobacterium tuberculosis* (*M.tb*) infection (LTBI), with 5-10% anticipated to develop TB disease over
95 their lifetime.² The elderly have a 1.5-fold risk of progressing to TB when compared to adults, and are
96 prone to severe treatment outcomes with 20-30% mortality.³⁻⁵ TB risk factors in the elderly include
97 higher prevalence of LTBI and a dysfunctional immune system, marked by inflammaging and oxidative
98 stress.^{3,6} Higher LTBI prevalence in older people is largely attributed to their lifetime-accumulated risk of
99 exposure to *M.tb*.⁷

100

101 LTBI detection is based on immunological memory to *M.tb* peptides, measured using either the
102 tuberculin skin test (TST) in-vivo or Interferon Gamma Release Assays (IGRAs) ex-vivo. The TST detects
103 recall immunity to intradermal *M.tb* purified protein derivative antigens.⁸ IGRAs are based on IFN- γ
104 production by peripheral blood mononuclear cells (PBMCs) in response to specific *M.tb* peptides.⁹⁻¹¹

105

106 Interpretation of TST and IGRAs has been challenging in elders due to several factors. First, TST
107 sensitivity is reported to decrease with older age¹², with higher false-negatives likely due to reduced
108 skin immunity with aging.^{13,14} Second, LTBI is highly heterogeneous in the elderly, due to a range of
109 recent or remote exposures to pulmonary TB patients. Third, studies comparing the performance of TST
110 vs. IGRAs (T-SPOT.TB vs. QuantiFERONS) show conflicting results, with most reporting lower sensitivity of
111 the TST, and among IGRAs, a higher sensitivity of the T-SPOT.TB vs. QuantiFERONS.¹⁵⁻¹⁷ When using
112 active TB as a gold standard, most studies report lower sensitivity in the elderly with all assays, but a
113 limitation of these studies is that most are done in hospitalized and severely ill patients.¹⁶⁻¹⁹ Another
114 limitation of these studies is the use of different QuantiFERON kit versions that are no longer
115 commercially available. Finally, most of these studies targeted elderly Asians, without data from
116 Hispanics.

117

118 To assess the performance of IGRAs for LTBI detection in elderly Hispanics, we conducted a cross-
119 sectional study comparing T-SPOT.TB and QuantiFERONS. We enrolled elderly community controls or
120 contacts of recent TB patients, with similar groups of younger adults as reference. Our findings indicated
121 a higher proportion of discordant, borderline or indeterminate findings in the elderly, but these
122 inconclusive results were always resolved as positive or negative with the other IGRA. LTBI prevalence

123 was similar with both IGRAs, and increased with age in the community controls, suggesting that IGRAs
124 are suitable for the assessment of LTBI in the elderly. We provide further insight into the clinical
125 interpretation of a positive IGRA in the elderly.

126

127 **METHODS**

128 **Participant Enrollment.** We enrolled adults (18-50 years) and elderly (>60 years) individuals in south
129 Texas and northeastern Mexico between 2017 and 2021. These included: 1) Individuals with exposure to
130 newly diagnosed TB patients for at least 5 hours within 6 months of enrollment (recent contacts; ReC);
131 and 2) Community controls (CoC) with no reported exposure or a remote history of exposure (> 6
132 months prior to enrollment) to a TB case. In addition, we enrolled individuals between 51 to 59 years
133 old, with the same enrollment and classification criteria as those mentioned for ReC or CoC. This study
134 was approved by human subjects institutional review boards in Mexico (110/2018/CEI) and the United
135 States (HSC-SPH-19-0308), and all participants signed a written informed consent.

136

137 **IGRAs.** Blood was collected at the time of enrollment and simultaneously evaluated for LTBI with T-
138 SPOT.TB (Oxford Immunotec) and a QuantiFERON test (Qiagen, Germantown). T-SPOT.TB evaluates the
139 IFN- γ response of blood CD4 T cell lymphocytes to *M.tb* antigens ESAT-6 (panel A) or CFP-10 (Panel B),
140 while the QFT-GIT evaluates these responses to the *M.tb* antigens ESAT-6, CFP-10, and TB7.7 (TB1).¹¹
141 The QFT-Plus contains a second tube with *M.tb* peptides that stimulate CD8 T cells (TB2).²⁰ During the
142 course of this study Qiagen transitioned from the QuantiFERON Gold In-tube (QFT-GIT) to QFT-Plus
143 (collectively referred to as QFT), with most participants tested with the QFT-Plus version (399/524,
144 76.1%). We did not find differences in their performance (**Supplementary Figure S1**). Indeterminate
145 results with QFTs due to either low mitogen responses or high backgrounds were categorized according
146 to the product inserts.⁹ When there was a borderline result with T-SPOT.TB or an indeterminate with
147 QFT, the positive or negative result with the other IGRA determined the final LTBI diagnosis.

148

149 **Data Analysis.** Data were analyzed using SAS vr. 9.4 (Cary, North Carolina). Chi-square or Fisher's exact
150 tests were used to compare categorical variables. Median values were compared by the Wilcoxon rank
151 sum test. Comparisons of medians between more than two study groups were established by the
152 Kruskal-Wallis test with post-hoc Dwass, Steel, Critchlow-Fligner (DSCF) method. The Cochran-Armitage
153 trend test was used to assess significant changes over different age groups. Cohen's kappa coefficient (k)
154 was used to measure overall agreement between paired test results.²¹ P values were considered

155 significant if ≤ 0.05 , and borderline significant if <0.10 . Graphs were plotted using GraphPad PRISM vr.
156 9.0.

157

158 RESULTS

159 IGRA prevalence across age groups

160 We enrolled 652 participants: 193 CoC (119 adults; 74 elderly) and 459 ReC (361 adults; 98 elderly), with
161 sociodemographic and clinical characteristics similar to a subset of this cohort described recently
162 (**Supplementary Table S1**).²² LTBI prevalence was significantly higher among elderly vs. adults in the CoC
163 group (56.7% in elderly vs. 23.2% adults; $p < 0.001$), but similar between age groups of ReC (elderly
164 71.3% vs. adults 64.1%; $p=0.233$; **Table 1**). We also found few host characteristics associated with LTBI
165 by univariable analysis (**Table 1**), with only macrovascular disease being more likely among the LTBI
166 elderly in the ReC group (adj-OR 2.14, 95%CI 1.11, 4.12; **Supplementary Table S1**).²²

167

168 Next, we evaluated how LTBI prevalence changes with increasing age in CoC vs. ReC groups, by 10-year
169 age intervals. For this analysis, we also included CoCs and ReCs who were between 51-59 years old ($n=$
170 111; **Supplemental material**). Results are shown for both IGRAs combined in **Fig. 1** (T-SPOT.TB and QFT)
171 or for the T-SPOT.TB and QFTs alone in **Supplementary Figure S2**. IGRA positivity increased with older
172 age among CoCs (trend $p < 0.001$), but remained consistently higher than 60% throughout all the studied
173 ages in the ReC group (trend $p = 0.329$). Our results also indicated that the proportion of new *M.tb*
174 infections among ReC was significantly higher in adults (mean 39.2%, 95%CI 29.6, 48.8%) when
175 compared to the elderly (mean 11.4%, 95%CI 5.2, 17.6%; $p < 0.050$; **Fig 1**). In summary, IGRA positivity
176 increased with age in elderly CoCs, but remained consistently higher throughout all the age groups in
177 the ReCs.

178

179 Concordance between IGRA assays

180 The proportion of elderly participants who tested IGRA positive was similar for T-SPOT.TB and QFT
181 assays: 45.7% vs. 42.9% in the CoC group and 54.1% vs. 62.6% in the ReC group (**Table 1**). Among
182 participants tested simultaneously with both types of IGRAs (518/652, 79.4%) in both CoC and ReC
183 groups, the overall concordance between IGRAs was 80.4% (kappa 0.694; moderate; **Fig 2**;
184 **Supplementary Table S2**). However, agreement between IGRAs differed by age groups. Among all
185 elderly, the concordance was 71.4% (kappa 0.478; weak), vs. 83.8% in adults (kappa 0.695; moderate).
186 When age groups were further stratified by CoC or ReC, IGRAs from the elderly also had a lower

187 concordance when compared to adults (CoC kappa: 0.342 vs. 0.719 in adults; ReC kappa: 0.532 vs. 0.660
188 in adults; **Fig 2; Supplementary Table S2**). Agreement was lower for the CoC vs. ReC, and particularly
189 low in the elderly (CoC: 65.4.2%, kappa 0.342, minimal; ReC: 74.8%, kappa 0.532, weak). In summary,
190 discordant results were highest among the elderly, and particularly in the CoC group (at 34.6%, **Fig 2**).

191
192 To determine the contribution of inconclusive results (indeterminate with QFTs or borderline with T-
193 SPOT.TB) to the discordance between IGRAs, we excluded participants with inconclusive results and re-
194 evaluated the data. The concordance between IGRAs improved in nearly all study groups
195 (**Supplementary Table S2**). Among all participants, the agreement improved by 7.5% (from 80.4% to
196 87.9% after exclusions). The largest improvement was among elderly ReC / from 74.4% to 89.2%), the
197 study group with the highest risk of TB.

198

199 **Interpretation of inconclusive results**

200 Given the contribution of borderline or indeterminate results to the discordance between IGRAs, we
201 expanded these analyses. Nearly all participants with borderline T-SPOT.TB results (n=28/30) and all
202 with indeterminate QFT results (n=17/17) were tested with both IGRAs simultaneously. In all cases, the
203 other IGRA resolved inconclusive findings, with all participants having a defined final classification as
204 positive or negative LTBI (upper panel of **Table 1**). In comparison, if only one IGRA would have been
205 performed per participant, the elderly would had higher proportion of borderline or indeterminate test
206 results when compared to adults. This difference was significant among the ReCs group (elderly 17.3%
207 vs. adults 7.2%; p=0.002), and had a similar trend for the smaller CoC group (elderly 4.0% vs. adults
208 1.7%; p=0.179; **Table 1**). Thus, elderly individuals had a higher likelihood of an inconclusive LTBI result
209 than adults.

210
211 We next determined if inconclusive results were more likely to be resolved as positive or negative with
212 the complementary IGRA (**Fig 3A-B**). We found that a borderline T-SPOT.TB result was resolved as
213 positive with the QFT in at least half the cases (14/28, 50% in adults; 7/11, 63.6% in elderly; **Fig 3**). In
214 contrast, an indeterminate result by QFT was resolved as positive with the T-SPOT.TB in 100% of the
215 cases: 17/17 among all participants tested, including 8/8 elderly. In all cases, indeterminate results were
216 due to high IFN- γ background. In summary, borderline T-SPOT.TB results were true 'borderline', while
217 indeterminate QFT results were always positive with the T-SPOT.TB.

218

219 IFN- γ response among LTBI participants

220 We evaluated if there were differences in the magnitude of response to *M.tb* antigens (number of IFN- γ
221 positive lymphocytes by T-SPOT.TB, or IFN- γ titers by QFT-Plus) by age group. Since the proportion of
222 IGRA-positives was higher in the elderly, the analysis was limited to those positive with any assay. In the
223 CoC group, there were no differences in the magnitude of IGRA responses to *M.tb* antigens between
224 ages (**Table 2**). In the ReC group, the elderly had fewer lymphocytes responsive to the ESAT-6 antigen (p
225 0.05), but all other responses to *M.tb* antigens were similar between age groups. The only consistent
226 alteration in the elderly vs. adults was their lower responsiveness to mitogens in the QFT-Plus assay, in
227 both the CoCs (p 0.064) and ReCs (p 0.073). These findings were confirmed when expanding our
228 analyses to all study participants, since the response to mitogens was not affected by the positivity of
229 the IGRA (CoC p< 0.001; ReC p=0.035). Finally, we found that regardless of age, a recent exposure to a
230 TB patient (ReC group) was associated with higher IFN- γ secretion vs. a remote exposure (CoC group;
231 **Supplementary Table S3**). In summary, older age was associated with lower responses to mitogens,
232 while the timing since exposure to an active TB case influenced the magnitude of the response to *M.tb*
233 antigens.

234

235 DISCUSSION

236 We evaluated the performance of IGRAs among Hispanic elderly vs. adults in ReC and CoC groups. This
237 design allowed us to compare the performance of the T-SPOT.TB and QFT assays across age groups, and
238 between participants with recent vs. remote exposure to active TB cases. Our design contrasts with
239 most previous studies, where IGRAs were evaluated among active TB cases across age groups, or as part
240 of outbreak investigations among the elderly.¹⁵⁻¹⁷ Furthermore, our analysis was done with QFT-Plus, in
241 contrast to previous studies that evaluated earlier versions of QFT.^{16,17,23}

242

243 There is a concern that the decline in the strength of the immune response in the elderly may decrease
244 the sensitivity of assays to detect LTBI in this population.²⁴ This limitation is observed for the TST^{12,17},
245 with a higher proportion of false negatives attributed to compromised skin immunity in the elderly.¹³ A
246 lower sensitivity has also been reported for IGRAs in the elderly, although less marked than with the
247 TST. However, these observations are from studies conducted amongst active TB patients, and with
248 false-negatives associated with very advanced TB disease, lymphopenia or malnutrition.^{16,17,25} Evaluation
249 of IGRAs in the elderly with TB in these studies may differ from results we obtained in those without TB
250 for several reasons. First, our elderly participants did not have severe underlying conditions that could

251 compromise their immunity, other than a high prevalence of diabetes that was not associated with their
252 LTBI status (**Supplementary Table S1**). Second, previous studies in participants with TB also reported
253 higher indeterminate results in the elderly, but these were due to low mitogen responses^{19,25}, while our
254 indeterminate results were due to high IFN- γ background. Third, we observed an increasing prevalence
255 of LTBI positives with age, even among individuals older than 60 years (**Fig 1**). However, we did not have
256 a gold standard for TB infection since active TB patients were not studied, and hence, cannot rule out a
257 lower sensitivity in the oldest participants (70 years+). We think this is unlikely because we did not
258 detect a notable defect in the magnitude of the cell-mediated immune responses to *M.tb* antigens in the
259 elderly when compared to adults (**Table 2**), and the prevalence of LTBI was similar when using T-
260 SPOT.TB vs. QFTs (**Supplementary Figure S2C**). Together, our results suggest that the sensitivity of IGRAs
261 for the detection of LTBI cases is not significantly impacted by old age alone.

262
263 Previous studies report challenges with IGRAs in the elderly vs. adults, namely poorer concordance
264 between IGRAs, or between IGRAs and the TST.¹⁵⁻¹⁷ Studies have also reported a higher proportion of
265 indeterminate results in older people.^{17,25-27} In our cohort, we also found that in the elderly vs. adults,
266 there was a lower concordance between IGRAs, and a higher proportion of indeterminate or borderline
267 results. We found a relationship between both observations, with discordant results being largely
268 attributed to inconclusive results. These unclear results hinder a physician's decision to recommend LTBI
269 treatment, in particular to elderly ReC who have a high risk of progression to active TB disease, and in
270 whom inconclusive results were the highest (17% of ReC elderly; **Table 1**). Importantly, in our cohort we
271 found that the resolution of inconclusive results was possible in 100% of cases with a complementary
272 IGRA, yielding a positive or negative result in a timely manner. The resolution of inconclusive results led
273 to improved concordance in all study groups, including in the elderly ReC: from a kappa of 0.532 (weak)
274 to 0.800 (strong; **Supplementary Table S2**). Thus, resolution of inconclusive results by testing with a
275 second IGRA is a time-efficient alternative when compared to the routine retesting of ReCs 8-10 weeks
276 later to confirm if there was a true conversion to a positive LTBI result.²⁸

277
278 The higher risk of active TB development among the elderly has been largely attributed to their waning
279 immune response.²⁴ For decades, this hypothesis has been based in part on data showing the lower
280 responsiveness of the elderly to the TST. Our results using IGRAs do not provide support for a marked
281 immunocompromised response to *M.tb* antigens in the elderly. First, we confirmed that the prevalence
282 of LTBI increases with age in the community, when using IGRAs that evaluate cell-mediated immunity to

283 *M.tb.* Second, the magnitude of the response to *M.tb* antigens in the CoC or ReC group was comparable
284 between the elderly and adults who were LTBI positive, and is consistent with a previous report.²⁵ Third,
285 the higher proportion of indeterminate results with the QFT in the elderly was due to a high IFN- γ
286 background in all cases, and not to low mitogen responses. Thus, higher indeterminate results in the
287 elderly may be a reflection of their baseline inflammatory status (inflammaging), or immune hyper-
288 responsiveness upon exposure to *M.tb* antigens.⁶ The lack of an evident compromise in T-cell responses
289 to *M.tb* in the elderly is consistent with findings from a recent study by our group.²⁹ Nevertheless, the
290 lower responsiveness of the elderly to the T-cell mitogen in the QFT-Plus assay (**Table 2**) suggests a
291 generalized defect in cell-mediated immunity, which is consistent with their reduced responsiveness to
292 vaccines.³⁰

293
294 The higher prevalence of LTBI in the elderly is thought to be a major contributing factor to their
295 increased risk of active TB development.^{3,31} However, in our cohort, the LTBI prevalence flattened at
296 around 70%, with a significantly lower proportion of new infections among the elderly vs. the adults (**Fig**
297 **1**). Thus, we posit that elderly individuals who are not markedly immunocompromised, may have a
298 higher resistance to LTBI conversion or active TB disease development compared to adults. There are
299 several observations supporting this possibility. First, a recent historical review of the literature among
300 individuals of all ages confirmed that active TB is more likely to develop shortly after initial infection,
301 with a dwindling risk up to two years, and rarely thereafter. Even though a case for the elderly is not
302 explicitly made, a bimodal distribution for the risk of TB reactivation is not observed over time.³² Second,
303 there are studies suggesting that LTBI-positive individuals may in fact be more protected from re-
304 infection with *M.tb.*^{7,33} Third, the interpretation of a positive LTBI result in individuals with remote
305 exposure is unclear, with some having a robust recall response to a past LTBI but no longer harboring
306 viable *M.tb.*³² Fourth, the elderly are more likely to have been exposed to *M.tb* during their lifetime,
307 even multiple times, and hence, are a select groups of survivors of active TB and LTBI.⁷ Thus, the higher
308 prevalence of positive LTBI tests among the elderly as a group is not necessarily a risk factor for active
309 TB disease development, except for individuals who still harbor dormant bacilli in granulomas and are
310 immunocompromised. Further studies are needed to understand the relationship between a positive
311 LTBI test result and the risk of progression to active TB disease, particularly for elderly contacts from
312 decades ago. These studies are critical to guide decisions on LTBI treatment in the elderly
313 population.^{14,34}

314

315 We recognize study limitations. First, there is no gold standard for LTBI assessment, so we based LTBI on
316 positivity with any of the two IGRAs tested. Second, we switched from the QFT-GIT to the QFT-PLUS kit
317 version during the course of our study, although 76.1% of the participants were evaluated with the –
318 PLUS kit and the performance of both kit versions was similar (**Supplementary Figure S1**). The inclusion
319 of both kits, therefore, allowed for additional analyses in our cohort; and in our hands, the additional
320 TB2 tube in the QFT-PLUS had a minor improvement in the sensitivity (about 2%; **Supplementary Table**
321 **S4**). This is expected, since the TB2 tube was mostly added to improve sensitivity in TB patients.³⁵ Third,
322 the cross-sectional nature of our design did not allow for the identification of the subset of elderly
323 participants with recent IGRA conversion, who are thought to have the highest risk of progression to
324 active TB disease. Finally, our study included elders with comorbidities such as diabetes and macro- and
325 micro-vascular diseases, but data cannot be extrapolated to those severely immunocompromised.

326
327 Overall, our results suggest that IGRAs are not affected by waning immunity in the elderly, which
328 contrasts with previous studies using the TST, or studies in the elderly with active TB. Furthermore,
329 despite a higher proportion of discordant or inconclusive results in the elderly vs. adults, the resolution
330 of inconclusive results was always possible when using a complementary IGRA. Thus, IGRAs are suitable
331 to evaluate LTBI in the elderly; however, despite the high prevalence of LTBI in the elderly, the
332 interpretation of a positive LTBI test (TST, IGRAs) should be interpreted with caution prior to
333 consideration of LTBI treatment.¹⁴

334

335

336 **Acknowledgements**

337 We would like to acknowledge Kristen Maynard, Danyelle Garza, Erica de Leon, Marielena Benavidez,
338 Jose A. Caso, Juan Carlos Lopez-Alvarenga and Fabiola Lopez for technical support. We also thank health
339 professionals and administrators at the Secretaría de Salud de Tamaulipas, including Q.F.B. Cristela
340 Resendez-Cardoso, Drs. Francisco Garcia-Luna Martinez and Ariel Mercado-Cárdenas (administration)
341 and Mr. Jorge Perez-Navarro (logistics). We also thank health professionals at the Casa Club del Adulto
342 Mayor, Sistema DIF Matamoros. We thank the study participants for their time and interest in this study.
343 Finally, we dedicate this study to the memory of our team members who were passionate about TB
344 research, and whom we lost to COVID-19 in 2020, Dr. Francisco Mora-Guzmán and R. Eminé Rodriguez-
345 Reyna.

346

347 **Funding**

348 Research reported in this publication was supported by the National Institute On Aging of the National
349 Institutes of Health under Award Number P01AG051428[P01-AG051428 to JT, LSS, BIR and JBT] and
350 NIH/NIA NRSA T32-AG021890 to JMS. The content is solely the responsibility of the authors and does
351 not necessarily represent the official views of the National Institutes of Health.

352

353 **Author contributions**

354 **Julia M. Scordo**: Original draft, data analysis, review and editing; **Genesis P. Aguillón-Duran, Eminé**
355 **Rodríguez-Reyna, Alejandro Villafañez**: Data collection and curation; **Doris Ayala, Ana Paulina Quirino-**
356 **Cerrillo, Mateo Ayala-Joya**: Data curation and specimen processing; **Larry Schlesinger, Jordi B.**
357 **Torrelles**: Conceptualization, review & editing; **Joanne Turner**: Conceptualization, Project
358 administration, Resources, review & editing; **Eder Ledezma-Campos, Francisco Mora-Guzmán**: Project
359 administration, review & editing; **Blanca I. Restrepo** (guarantor): Conceptualization, Project
360 administration, data analysis, review & editing. **All authors**: Reviewed and approved the final version.

361

362 **Conflicts of interest**

363 BIR received funding support from Oxford Immunotec for an unrelated study. Other authors declare no
364 conflicts of interest.

365

366

367 References

- 368 1. World-Health-Organization. Global tuberculosis report 2020.
369 <https://www.who.int/publications/i/item/9789240013131>. 2020.
370 <https://www.who.int/publications/i/item/9789240013131>. Accessed 2021.
- 371 2. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using
372 Mathematical Modelling. *PLoS Med*. 2016;13(10):e1002152.
- 373 3. Hochberg NS, Horsburgh CR, Jr. Prevention of tuberculosis in older adults in the United States:
374 obstacles and opportunities. *Clin. Infect. Dis*. 2013;56(9):1240-1247.
- 375 4. Abdelbary BE, Garcia-Viveros M, Ramirez-Oropesa H, Rahbar MH, Restrepo BI. Predicting
376 treatment failure, death and drug resistance using a computed risk score among newly
377 diagnosed TB patients in Tamaulipas, Mexico. *Epidemiol. Infect*. 2017;145(14):3020-3034.
- 378 5. Garcia-Goez JF, Velez JD, Mora BL, et al. Tuberculosis in elderly patients in the city of Cali,
379 Colombia: a hospital-based cohort study. *J Bras Pneumol*. 2020;46(5):e20200072.
- 380 6. Piergallini TJ, Turner J. Tuberculosis in the elderly: Why inflammation matters. *Exp Gerontol*.
381 2018;105:32-39.
- 382 7. Dutt AK, Stead WW. Tuberculosis in the elderly. *Med Clin North Am*. 1993;77(6):1353-1368.
- 383 8. Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN. Mantoux Test as a model for a
384 secondary immune response in humans. *Immunol. Lett*. 2006;107(2):93-101.
- 385 9. T-SPOT.TB Package insert. 2017.
- 386 10. QuantiFERON-TB Gold (QFT) ELISA Package Insert. 2016; [http://www.quantiferon.com/wp-](http://www.quantiferon.com/wp-content/uploads/2017/04/English_QFT_ELISA_R04_082016.pdf)
387 [content/uploads/2017/04/English_QFT_ELISA_R04_082016.pdf](http://www.quantiferon.com/wp-content/uploads/2017/04/English_QFT_ELISA_R04_082016.pdf).
- 388 11. QuantiFERON-TB Gold. http://www.cellestis.com/IRM/contentAU/gold/Gold_PackageInsert.pdf.
389 http://www.cellestis.com/IRM/contentAU/gold/Gold_PackageInsert.pdf.
- 390 12. Dorken E, Grzybowski S, Allen EA. Significance of the tuberculin test in the elderly. *Chest*.
391 1987;92(2):237-240.
- 392 13. Agius E, Lacy KE, Vukmanovic-Stejic M, et al. Decreased TNF-alpha synthesis by macrophages
393 restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. *J. Exp. Med*.
394 2009;206(9):1929-1940.
- 395 14. Zevallos M, Justman JE. Tuberculosis in the elderly. *Clin Geriatr Med*. 2003;19(1):121-138.
- 396 15. Ferrara G, Losi M, D'Amico R, et al. Interferon-gamma-release assays detect recent tuberculosis
397 re-infection in elderly contacts. *Int. J. Immunopathol. Pharmacol*. 2009;22(3):669-677.
- 398 16. Bae W, Park KU, Song EY, et al. Comparison of the Sensitivity of QuantiFERON-TB Gold In-Tube
399 and T-SPOT.TB According to Patient Age. *PLoS One*. 2016;11(6):e0156917.
- 400 17. Kobashi Y, Sugiu T, Shimizu H, et al. Clinical evaluation of the T-SPOT.TB test for patients with
401 indeterminate results on the QuantiFERON TB-2G test. *Internal medicine (Tokyo, Japan)*.
402 2009;48(3):137-142.
- 403 18. Kwon YS, Kim YH, Jeon K, et al. Factors that Predict Negative Results of QuantiFERON-TB Gold In-
404 Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort
405 Study. *PLoS One*. 2015;10(6):e0129792.
- 406 19. Jeon YL, Nam YS, You E, et al. Factors influencing discordant results of the QuantiFERON-TB Gold
407 In-tube test in patients with active TB. *J. Infect*. 2013;67(4):288-293.
- 408 20. QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert. 2020;
409 [https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-](https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-Plus-ELISA-IFU.pdf)
410 [Plus-ELISA-IFU.pdf](https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-Plus-ELISA-IFU.pdf).
- 411 21. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)*. 2012;22(3):276-
412 282.

- 413 22. Scordo JM, Aguillón-Duran GP, Ayala D, et al. A prospective cross-sectional study of tuberculosis
414 in elderly Hispanics reveals that BCG vaccination at birth is protective whereas diabetes is not a
415 risk factor Submitted.
- 416 23. Xin H, Zhang H, Liu J, et al. Mycobacterium Tuberculosis infection among the elderly in 20 486
417 rural residents aged 50-70 years in Zhongmu County, China. *Clin. Microbiol. Infect.*
418 2019;25(9):1120-1126.
- 419 24. Byng-Maddick R, Noursadeghi M. Does tuberculosis threaten our ageing populations? *BMC*
420 *Infect. Dis.* 2016;16:119.
- 421 25. Tebruegge M, de Graaf H, Sukhtankar P, et al. Extremes of age are associated with
422 indeterminate QuantiFERON-TB gold assay results. *J. Clin. Microbiol.* 2014;52(7):2694-2697.
- 423 26. Chee CB, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two commercial gamma
424 interferon release assays for pulmonary tuberculosis. *J. Clin. Microbiol.* 2008;46(6):1935-1940.
- 425 27. Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of the QuantiFERON TB-2G test for elderly
426 patients with active tuberculosis. *Chest.* 2008;133(5):1196-1202.
- 427 28. Mazurek GH, Jereb J, LoBue PA, Iademarco MF, Metchock B, Vernon AA. Guidelines for using the
428 QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.
429 *MMWR.* 2005;54(RR15):49-55. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a4.htm>.
- 430 29. Ault R, Dwivedi V, Koivisto E, et al. Altered monocyte phenotypes but not impaired peripheral T
431 cell immunity may explain susceptibility of the elderly to develop tuberculosis. *Exp Gerontol.*
432 2018;111:35-44.
- 433 30. Abarca Tomas B, Pell C, Bueno Cavanillas A, Guillen Solvas J, Pool R, Roura M. Tuberculosis in
434 migrant populations. A systematic review of the qualitative literature. *PLoS One.*
435 2013;8(12):e82440.
- 436 31. Horsburgh CR, Jr., O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a
437 population-based approach. *Am. J. Respir. Crit. Care Med.* 2010;182(3):420-425.
- 438 32. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. *BMJ.*
439 2018;362:k2738.
- 440 33. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to
441 active tuberculosis following reinfection with Mycobacterium tuberculosis. *Clin. Infect. Dis.*
442 2012;54(6):784-791.
- 443 34. Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis
444 Infection: Recommendations from the National Tuberculosis Controllers Association and CDC,
445 2020. *MMWR Recomm Rep.* 2020;69(1):1-11.
- 446 35. Petruccioli E, Scriba TJ, Petrone L, et al. Correlates of tuberculosis risk: predictive biomarkers for
447 progression to active tuberculosis. *Eur. Respir. J.* 2016;48(6):1751-1763.

448

449

450 **Figure Legends**

451

452 **Figure 1. Changes in the prevalence of IGRA-positive results across age groups.** The prevalence of LTBI
453 was based on a positive T-SPOT.TB or QuantiFERON assay (QFT-GIT or QFT-Plus). The prevalence of LTBI
454 increased with age among the CoC (P for trend = <0.001), but not for ReC (P for trend = 0.354). LTBI was
455 significantly higher among CoC versus ReC up until 59 years old (non-overlapping 95% confidence
456 intervals), but not among those 60 years or older. The proportion of newly-infected individuals in the
457 ReC groups was calculated by subtracting LTBI-positives from the baseline CoC group (line with
458 triangles). CoC, Community controls; ReC, Recent contacts; LTBI, latent *M. tuberculosis* infection.
459 Vertical bars, 95% confidence intervals for LTBI prevalence.

460

461 **Figure 2. Concordance between IGRA assays, by age and study groups.** The percent of positive and
462 negative agreement was estimated for participants in whom both types of IGRA assays was done
463 simultaneously (N=518/652, 79.4%), by age and study groups. The sample size and kappa statistic (k) is
464 provided for each study group. CoC, Community controls; ReC, Recent contacts.

465

466 **Figure 3. Resolution of inconclusive IGRAs. A.** Among all study participants, borderline T- SPOT.TB was
467 positive in 50% (14/28) of the cases by QFT, while indeterminate QFTs were positive by T- SPOT.TB in
468 100% (17/17) of the cases. **B.** Among all elderly, borderline T- SPOT.TB was positive in 64% (7/11) of the
469 cases by QFT, while indeterminate QFTs were positive by T- SPOT.TB in 100% (8/8) of the cases.

470

471

472

473

474

475

476

477

478

479

480

Table 1. LTBI test results among elderly and young adults, by exposure history

	Community & Recent Contacts			Community			Recent Contacts		
	Young adults	Elderly	P value	Young adults	Elderly	P value	Young adults	Elderly	P value
	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)	
T-SPOT.TB and QFT combined^a			0.075			< 0.001			0.641
Negative	219 (45.6)	65 (37.8)		92 (77.3)	33 (44.6)		127 (35.2)	32 (32.7)	
Positive	261 (54.4)	107 (62.2)		27 (22.7)	41 (55.4)		234 (64.8)	66 (67.4)	
T-SPOT.TB			0.264			0.002			0.124
Negative	230 (48.0)	72 (42.9)		92 (77.3)	37 (52.9)		138 (38.3)	35 (35.7)	
Borderline	19 (4.0)	11 (6.6)		2 (1.7)	1 (1.4)		17 (4.7)	10 (10.2)	
Positive	230 (48.0)	85 (50.6)		25 (21.0)	32 (45.7)		205 (56.9)	53 (54.1)	
QFT			0.117			< 0.001			0.177
Negative	173 (46.0)	58 (39.5)		58 (85.3)	30 (53.6)		115 (37.3)	28 (30.8)	
Indeterminate	9 (2.4)	8 (5.4)		0 (0.0)	2 (3.6)		9 (2.9)	6 (6.6)	
Positive	194 (51.6)	81 (55.1)		10 (14.7)	24 (42.9)		184 (59.7)	57 (62.6)	
Borderline or indeterminate^b			0.012			0.313			0.002
Positive or negative	452 (94.2)	152 (88.4)		117 (98.3)	71 (96.0)		335 (92.8)	81 (82.7)	
Borderline or indeterminate	28 (5.8)	20 (11.6)		2 (1.7)	3 (4.0)		26 (7.2)	17 (17.3)	

^a Presence of LTBI was based on a positive T-SPOT.TB or QuantiFERON (QFT) assays (Gold In-tube or QuantiFERON-Plus).

^b Borderline results with T-SPOT.TB or indeterminate with QFT. Differences between groups established by Chi-square test. Statistically significant or borderline significant differences are in bold text.


Table 2. Magnitude of IGRA responses, among participants positive for LTBI^{a,b}

	Community					Recent Contacts				
	Adults		Elderly		P value	Adults		Elderly		P value
	n	Median (IQR)	n	Median (IQR)		n	Median (IQR)	n	Median (IQR)	
T-SPOT.TB										
Nil	29	0 (0.0)	42	0 (1.0)	0.281	244	0 (1.0)	69	0 (0.0)	0.023
ESAT6 - Nil	29	10 (21.0)	42	10.5 (17)	0.760	244	18 (19.0)	69	10 (17.0)	0.050
CFP10 - Nil	29	16 (18.0)	42	20 (20)	0.767	244	22 (17.0)	69	22 (20.0)	0.998
QFT-Plus										
Nil	14	0.2 (0.6)	31	0.2 (0.6)	0.787	139	0.4 (1.4)	44	0.5 (1.8)	0.764
Mit-Nil	14	21.4 (16.0)	31	15.4 (15.5)	0.064	139	21.0 (11.6)	44	15.5 (15.5)	0.073
TB1 - Nil	14	0.4 (10.2)	31	0.6 (1.8)	0.806	139	4.2 (6.6)	44	3.8 (6.5)	0.436
TB2 - Nil	14	0.5 (8.2)	31	0.7 (2.5)	0.902	139	4.1 (7.1)	44	3.9 (6.5)	0.349
Mit-Nil (all) ^c	53	25.6 (13.9)	56	15.5 (3.6)	^{<} 0.001	219	21.3 (11.5)	71	16.1 (14.4)	0.035

^a Participants with positive IGRAs included those with borderline or indeterminate results who were classified as positive based on the other IGRA assay;

^b Values from the indeterminate reactions were excluded due to their high non-specific IFN- γ background;

^c Mitogen responses were also evaluated for all study participants, including those who tested IGRA-negative; Mit, mitogen; Group medians were compared by the Wilcoxon rank sum test; Statistically significant or borderline significant differences are in bold text.




Adult + Elderly


Adult

Elderly


**CoC
+
ReC**



n=518; κ =0.634; P= 0.030




n=375; κ =0.695; P= 0.034




n=143; κ =0.478; P= 0.063


CoC



n=120; κ =0.521; P= 0.080




n=68; κ =0.719; P= 0.119




n=52; κ =0.342; P= 0.120


ReC



n=398; κ =0.631; P= 0.035




n=307; κ =0.660; P= 0.039



n=91; κ =0.532; P= 0.076

■ % Pos agreement
 ■ % Neg agreement
 ■ % Discordant

A. All study participants
Borderline T-SPOT.TB Indeterminate QFT



B. All elderly
Borderline T-SPOT.TB Indeterminate QFT

